Black Titan Corp (NASDAQ:BTTC) Sees Significant Growth in Short Interest

Posted by Latisha Jones on Aug 27th, 2026

Black Titan Corp (NASDAQ:BTTC – Get Free Report) saw a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 395,561 shares, a growth of 3,080.8% from the July 30th total of 12,436 shares. Approximately 3.7% of the company’s stock are short sold. Based on an average daily trading volume, of 2,396,917 shares, the short-interest ratio is currently 0.2 days.

Black Titan Trading Down 6.1%

Black Titan stock opened at $0.49 on Thursday. Black Titan has a 12 month low of $0.48 and a 12 month high of $39.00. The company has a quick ratio of 4.62, a current ratio of 4.62 and a debt-to-equity ratio of 0.06. The stock has a market cap of $5.27 million, a P/E ratio of -0.17 and a beta of 1.23. The company’s fifty day simple moving average is $0.75 and its 200-day simple moving average is $1.12.

Black Titan (NASDAQ:BTTC – Get Free Report) last announced its quarterly earnings data on Friday, June 12th. The company reported ($0.22) earnings per share (EPS) for the quarter. The company had revenue of $0.59 million during the quarter.

Institutional Investors Weigh In On Black Titan

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in shares of Black Titan in the 4th quarter valued at approximately $26,000. HRT Financial LP bought a new position in Black Titan during the fourth quarter valued at approximately $28,000. Marex Group plc bought a new position in Black Titan during the fourth quarter valued at approximately $84,000. Finally, Armistice Capital LLC acquired a new stake in Black Titan in the fourth quarter valued at approximately $840,000.

About Black Titan

(Get Free Report)

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.